Leuprolide: Uses, Mechanism, Evidence, and Side Effects

Men diagnosed with advanced prostate cancer often want to understand how hormone-based therapy actually works before starting treatment. Leuprolide is one of the most established drugs in this category, with decades of clinical use behind it.

Key takeaways

• Leuprolide is a GnRH agonist marketed under the brand name Vabrinty.
• It is approved specifically for the treatment of advanced prostate cancer.
• The drug works by suppressing the hormones that drive testosterone production.
• More than 500 registered clinical trials have studied leuprolide or involved it as part of treatment regimens.
• The most commonly reported adverse events in safety databases include hot flushes and fatigue.

What Leuprolide Is

Leuprolide acetate belongs to a class of medicines called GnRH (gonadotropin releasing hormone) agonists. When given continuously at therapeutic doses, it inhibits the secretion of gonadotropins, hormones that signal the testes and ovaries to produce steroid hormones. Animal and human studies show that after an initial, temporary stimulation phase, ongoing use suppresses testicular and ovarian steroidogenesis. This hormone-lowering effect reverses once the drug is stopped.

What Leuprolide Is Approved For

Leuprolide, sold as Vabrinty, is indicated for the treatment of advanced prostate cancer. As a GnRH agonist, it lowers testosterone levels that can fuel the growth of prostate cancer cells. The current label does not carry a boxed warning.

What the Evidence Shows

Leuprolide has been studied or used across more than 500 registered clinical trials. Among the sampled studies, one completed Phase 1/2 trial evaluated docetaxel combined with androgen ablation and external-beam radiation in men with high-risk localized prostate cancer. A separate completed Phase 2 trial examined chemotherapy, hormone therapy, and radiation therapy in patients with locally advanced disease.

Reported Side Effects

Safety reports submitted to adverse event databases reflect counts of reported occurrences, not confirmed incidence or proven causation. The most frequently reported reaction is hot flush, with 9,645 reports, followed by fatigue (5,246) and injection site pain (4,924). A substantial share of reports relate to product handling and administration, including preparation errors, syringe issues, device leakage, and technique problems, rather than to the drug's biological effects alone. Death was also among the reported terms, underscoring that these figures capture reported events in patients receiving treatment for serious underlying disease, not a measured rate of fatal outcomes caused by the drug.